VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
AAPGAscentage Pharma Group International
$16.77$1.6B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksAAPGRevenue History

AAPG logoAscentage Pharma Group International (AAPG) Revenue History

Annual and quarterly revenue from 2016 to present

TTM Revenue$1.55B▲ +$990.0M vs FY2025
YoY Growth+113.0%Excellent
Q4 2025$334.1M+113.0% YoY · +43.0% QoQ
Revenue CAGR
3Y+38.6%
→
5Y+114.0%
→
10Y—
Growth decelerating ↓
Best Fiscal Year$980.6M (2024)
Best Quarter$823.7M (Q2 2024)
Revenue per Share$16.72
Revenue per Employee$2.7M

AAPG Revenue Over Time (2016–2025)

AAPG Revenue Growth History

6 of 9 years with positive growth
Annual Revenue Growth · Each cell = one fiscal year
2016—
2017-17.5%
2018+7.6%
2019+113.2%
2020-14.2%
2021+124.2%
2022+651.4%
2023+5.9%
2024+341.8%
2025-43.1%
FY2016 revenue growth
N/A
FY2017 revenue growth
-17.5%
FY2018 revenue growth
+7.6%
FY2019 revenue growth
+113.2%
FY2020 revenue growth
-14.2%
FY2021 revenue growth
+124.2%
FY2022 revenue growth
+651.4%
FY2023 revenue growth
+5.9%
FY2024 revenue growth
+341.8%
FY2025 revenue growth
-43.1%
DeclineStrong growth
↓ 1-year revenue declineBest: +651.4% (FY2022)Worst: -43.1% (FY2025)
Recent Quarterly Revenue & YoY Growth
QuarterRevenueYoY
Q4 2025$334.1M+113.0%
Q2 2025$233.7M-71.6%
Q4 2024$156.9M+97.9%
Q2 2024$823.7M+477.3%
Q4 2023$79.3M-24.4%
Q2 2023$142.7M+36.1%
Q4 2022$104.9M+601.6%
Q2 2022$104.9M+708.8%

AAPG Revenue Analysis (2016–2025)

Current Revenue & Growth

As of June 28, 2026, Ascentage Pharma Group International (AAPG) generated trailing twelve-month (TTM) revenue of $1.55 billion, reflecting explosive growth of +113.0% year-over-year. The most recent quarter (Q4 2025) recorded $334.1 million in revenue, up 43.0% sequentially.

Historical Growth Trajectory

AAPG's 5-year compound annual growth rate (CAGR) stands at +114.0%, indicating outstanding long-term growth trajectory. The 3-year CAGR of +38.6% is below the 5-year average, signalling a growth deceleration in recent years. Ascentage Pharma Group International's highest annual revenue of $980.6 million was recorded in 2024.

Peer Comparison

Compared to Healthcare sector peers — including ABBV (+9.5% YoY), BCAB (-81.8% YoY), and KYMR (-12.6% YoY) — AAPG has outperformed the peer group in revenue growth. Compare AAPG vs ABBV →

AAPG Revenue vs Peers

Revenue metrics vs comparable public companies

CompanyTTM RevenueYoY Growth5Y CAGROp. MarginCompare
AAPG logoAAPGCurrent$1.5B+113.0%+114.0%-211.1%
ABBV logoABBV$61.2B+9.5%+6.0%32.8%
BCAB logoBCAB$2M-81.8%+36.1%-2965.3%
KYMR logoKYMR$39M-12.6%+2.9%-891.3%
ARVN logoARVN$263M-79.1%+58.9%-43.8%
Best in groupLowest in group

AAPG Historical Revenue Data (2016–2025)

1–10 of 10 records
Year Revenue YoY % Gross Profit Gross Margin Op. Income Op. Margin
2025$558.5M-43.1%$426.7M76.4%$-1,179,161,166-211.1%
2024$980.6M+341.8%$951.6M97.0%$-369,730,000-37.7%
2023$222.0M+5.9%$191.4M86.2%$-872,636,000-393.1%
2022$209.7M+651.4%$187.7M89.5%$-849,810,000-405.2%
2021$27.9M+124.2%$24.6M88.1%$-869,835,000-3116.6%
2020$12.4M-14.2%$10.5M84.2%$-663,941,000-5332.9%
2019$14.5M+113.2%$12.4M85.6%$-582,685,000-4014.9%
2018$6.8M+7.6%$6.8M100.0%$-345,443,612-5074.8%
2017$6.3M-17.5%$6.3M100.0%$-130,668,000-2064.9%
2016$7.7M-$7.4M96.6%$-114,622,000-1495.0%
Consensus-Based Analysis Tools

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10+ years return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

AAPG — Frequently Asked Questions

Quick answers to the most common questions about buying AAPG stock.

Is AAPG's revenue growth accelerating or slowing?

AAPG revenue growth is accelerating. TTM revenue reached $1.5B, up +113.0% year-over-year — ahead of the 5-year CAGR of +114.0%. This indicates the business is expanding faster than its historical baseline.

What is AAPG's revenue history from 2016 to 2026?

Ascentage Pharma Group International (AAPG) revenue history spans 2016 to 2026. TTM revenue as of 2026 is $1.5B, growing at +113.0% YoY. The 5-year CAGR is +114.0%. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.

What is AAPG's long-term revenue growth rate (CAGR)?

Ascentage Pharma Group International's 5-year revenue CAGR of +114.0% reflects the sustained nature of its business expansion. As of 2026, the current YoY growth rate of +113.0% is above this long-term average. CAGR is the most reliable measure of sustained revenue momentum for AAPG.

Why does AAPG's quarterly revenue fluctuate?

AAPG quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Ascentage Pharma Group International's revenue data from 2016 to 2026 shows full historical quarterly detail on this page.

How is AAPG's revenue distributed by segment?

AAPG reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.

How does AAPG's revenue compare to industry peers?

Ascentage Pharma Group International (AAPG) with TTM revenue of $1.5B and +113.0% YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.